Bicara Therapeutics/$BCAX
1D1W1MYTD1Y5YMAX
Capital at risk
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
- Ticker
- $BCAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- Boston, United States
- Website
- www.bicara.com
BCAX Metrics
BasicAdvanced
$1.5B
-
-$3.11
-
-
Price and volume
Market cap
$1.5B
52-week high
$30.99
52-week low
$10.30
Average daily volume
607K
Financial strength
Current ratio
11.589
Quick ratio
11.438
Total debt to equity
0.248
Profitability
EBITDA (TTM)
-201.834
Effective tax rate (TTM)
-0.11%
Management effectiveness
Return on assets (TTM)
-26.14%
Return on equity (TTM)
-41.01%
Valuation
Price to book
3.28
Price to tangible book (TTM)
3.28
Price to free cash flow (TTM)
-10.283
Free cash flow yield (TTM)
-9.72%
Free cash flow per share (TTM)
-2.27
Growth
Earnings per share change (TTM)
32.30%
Bulls say / Bears say
Bicara’s cash, cash equivalents and marketable securities of $539.8 million as of March 31, 2026 are expected to fund operations into the first half of 2029, providing runway for pivotal trials without near-term fundraising needs (GlobeNewswire).
The company selected 1500 mg weekly of ficerafusp alfa as the optimal Phase 3 dose based on Phase 1b biomarker analyses showing greater TGF-β inhibition, stronger immune activation, and deeper clinical responses, derisking the pivotal study (GlobeNewswire).
An interim analysis of the FORTIFI-HN01 Phase 2/3 trial is expected in mid-2027, potentially supporting FDA accelerated approval and derisking the path to market before full enrollment completion (GlobeNewswire).
Attempting to secure additional financing may divert management from day-to-day development of ficerafusp alfa, potentially delaying clinical progress and increasing execution risk (SEC EDGAR).
Enrollment delays in the ~650-patient FORTIFI-HN01 pivotal trial could postpone the mid-2027 interim analysis and derail the planned accelerated approval timeline (GlobeNewswire).
The initiation of an alternate loading and every-three-week maintenance dosing study in Q3 2026 adds development complexity, heightens costs, and introduces regulatory uncertainty that may delay accelerated approval if results are not timely (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 14 Aug 2026.
Upcoming events
No upcoming events
BCAX News
AllArticlesVideos
Funds containing BCAX
AllUSDGBPEUR
Fund name | Fund size | $BCAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
iShares Nasdaq US Biotechnology£BTEK | £867M | 0.12% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.